Skip to main content

Table 1 Detailed clinicopathological characteristics of the patient population

From: Characterization of the hepatitis B virus DNA detected in urine of chronic hepatitis B patients

Sample ID

Age

Gender

Liver Disease

 

Serum Analysis

Urine analysis

Any known kidney disease

Anti-viral therapy

HBV viral load category

HBV viral Load (IU/mL)

HBeAg (+/−)

HBsAg (+/−)

AST (IU/L)

ALT (IU/L)

AFP (ng/ml)

RBC/ High power field

Urine albumin (mg/dL)

1

29

F

Cirrhosis

High

1.70E + 08

+

+

44

36

< 1.3

2~ 5

30

No

2

36

F

CHB

High

1.70E + 08

+

+

20

17

1.7

0

CKD

No

3

32

M

CHB

High

1.70E + 08

+

+

33

64

1.3

0~ 2

No

4

41

F

Cirrhosis

High

1.34E + 08

+

+

191

126

5.8

2~ 5

Yes

5

52

F

CHB

High

6.07E + 07

+

+

23

21

4

0~ 2

10

FSGS,CGN

No

6

52

M

Cirrhosis

High

5.81E + 07

+

+

109

48

81

0~ 2

Yes

7

68

F

Cirrhosis

High

4.57E + 07

+

+

73

38

3.6

2~ 5

200

Yes

8

29

F

CHB

High

4.53E + 07

+

+

48

60

1.8

0~ 2

No

9

32

M

CHB

High

4.13E + 07

+

+

394

921

16.4

0~ 2

Yes

10

22

M

CHB

High

3.04E + 07

+

+

160

556

5.2

0

No

11

54

M

CHB

High

1.44E + 07

+

24

25

2.8

0

No

12

72

F

CHB

High

3.89E + 06

+

58

62

35.1

0~ 2

No

13

59

M

CHB

High

1.78E + 06

+

69

97

4.3

0~ 2

No

14

65

M

CHB

High

1.37E + 06

+

60

110

5

0~ 2

No

15

60

F

CHB

High

8.30E + 05

+

171

242

2.8

0~ 2

Yes

16

42

M

CHB

High

7.47E + 05

+

22

24

< 1.3

2~ 5

Yes

17

55

F

CHB

High

7.25E + 05

+

+

299

424

7.4

0~ 2

Yes

18

60

M

Cirrhosis

High

4.17E + 05

+

64

63

32.8

0~ 2

No

19

36

M

CHB

High

3.38E + 05

+

+

34

50

4.2

2~ 5

10

Yes

20

60

F

CHB

High

3.19E + 05

+

99

124

2.6

0~ 2

No

21

41

M

CHB

High

2.10E + 05

+

89

207

6.5

0

No

22

48

M

CHB

High

1.67E + 05

+

31

35

< 1.3

0

No

23

63

F

CHB

High

1.48E + 05

+

43

30

1.9

0~ 2

No

24

65

F

HCC

High

1.08E + 05

+

+

186

95

2623.1

0~ 2

No

25

62

M

CHB

High

1.02E + 05

+

27

39

3.4

0~ 2

No

26

48

F

CHB

Low

9.31E + 04

+

28

31

3.3

0~ 2

No

27

46

M

CHB

Low

4.85E + 04

+

33

53

2.1

0

No

28

67

F

CHB

Low

3.93E + 04

+

38

27

5

0

No

29

52

M

CHB

Low

3.82E + 04

+

32

37

4.1

0~ 2

No

30

75

F

CHB

Low

2.75E + 04

+

41

30

3.4

2~ 5

Yes

31

31

M

CHB

Low

2.65E + 04

+

+

38

57

< 1.3

0

Yes

32

44

M

Cirrhosis

Low

1.74E + 04

+

+

72

95

2.4

> 100

70

No

33

48

F

CHB

Low

1.65E + 04

+

22

22

< 1.3

0

No

34

54

M

CHB

Low

1.49E + 04

+

40

52

< 1.3

0~ 2

10

No

35

51

F

CHB

Low

1.01E + 04

+

36

22

1.4

2~ 5

NA

No

36

48

M

CHB

Low

9.68E + 03

+

38

30

6.7

0~ 2

600

No

37

53

F

CHB

Low

6.40E + 03

+

46

81

2.1

0~ 2

No

38

59

M

CHB

Low

4.36E + 03

+

44

25

2.1

0~ 2

Yes

39

46

M

CHB

Low

4.08E + 03

+

27

35

5.2

0

No

40

18

M

CHB

Low

3.18E + 03

+

+

45

78

1.6

0~ 2

10

No

41

57

M

CHB

Low

3.00E + 03

+

29

38

3.5

0~ 2

Yes

42

57

F

Cirrhosis

Low

2.93E + 03

+

33

44

1.4

0~ 2

No

43

28

M

CHB

Low

2.68E + 03

+

35

48

21.4

0~ 2

30

No

44

47

M

CHB

Low

2.42E + 03

+

42

82

2.1

2~ 5

10

No

45

64

F

CHB

Low

2.24E + 03

+

58

67

3.9

0~ 2

No

46

58

M

CHB

Low

2.02E + 03

+

26

28

< 1.3

0~ 2

20

No

47

43

F

CHB

Low

1.83E + 03

26

26

6.2

2~ 5

No

48

56

F

CHB

Low

1.50E + 03

+

26

23

2.4

0~ 2

No

49

33

F

CHB

Low

1.49E + 03

+

28

42

3.2

0~ 2

No

50

56

F

CHB

Low

1.25E + 03

+

34

67

2.6

2~ 5

Yes

51

38

M

CHB

Low

1.17E + 03

+

43

91

5

0~ 2

No

52

38

M

CHB

Low

1.09E + 03

+

38

77

2.4

0~ 2

10

No

53

61

M

CHB

Low

1.07E + 03

+

26

30

2.1

0~ 2

No

54

51

M

CHB

Low

1.06E + 03

+

21

27

2.8

0

No

55

28

F

CHB

Low

3.41E + 02

+

36

32

2.7

0~ 2

Yes

56

34

M

CHB

Low

5.40E + 01

+

32

53

2.4

0

Yes

57

36

M

CHB

Low

3.20E + 01

+

+

116

98

3.5

2~ 5

50

Yes

58

69

M

HCC

Low

2.00E + 01

+

45

21

5060.9

> 100

30

No

59

40

M

CHB

Low

2.00E + 01

41

65

3.8

0

Yes

60

38

M

CHB

Low

< 20

+

46

57

7.7

0~ 2

Yes

  1. F female, M male, CHB Chronic hepatitis B infection, NA Data not available, CKD chronic kidney disease, FSGS focal segmental glomerulosclerosis, CGN chronic glomerulonephritis
  2. For all patients who received antiviral treatment, the drug received was “Telbivudine,” which has no known renal side effects